The study examined the combination of atezolizumab with FOLFOX chemotherapy in patients with stage III mismatch repair–deficient colon cancer. The research was published in the New England Journal of Medicine, Volume 394, Number 12, Pages 1155-1166, on March 26, 2026. The main objective was to assess the effectiveness of this combined treatment after surgery. The study provided key findings on safety and efficacy in patients with this type of tumor. FOLFOX consists of the drugs LV/5-fluorouracil and oxaliplatin, which are commonly used in the treatment of colorectal cancer. Combination with immunotherapy such as atezolizumab targets PD-1/PD-L1 mechanisms. The results show the potential to improve survival compared with standard regimens.